Please login to the form below

Not currently logged in
Email:
Password:

Dr Martin Rothman joins Sofinnova Partners

He becomes the firm’s venture partner

RothmanLife Science-focused European venture capital firm, Sofinnova Partners, has appointed Dr Martin Rothman as venture partner.

Rothman brings 40 years of experience along with an international network in the medical field to Sofinnova Partners. There, he will focus on helping the team identify and evaluate “promising” medical device companies.

His new position at the firm will also see him take on a mentor role, as he will guide entrepreneurs and physicians launching clinical innovations.

Rothman said: “I am thrilled to join Sofinnova Partners’ team as venture partner.

“We share a common vision of entrepreneurship and a passion for bringing innovative therapies to patients and the medical community.”

Until recently, Rothman was vice president of medical affairs for coronary, structural heart and renal denervation for Medtronic, where he held that position since 2010.

Commenting on the appointment, Antoine Papiernik, managing partner and chairman of Sofinnova Partners, said: “Martin is an exceptional physician and repeat entrepreneur.

“His experience ideally complements our team and represents a key asset for Sofinnova Partners at a time when our activity is growing.”

22nd May 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics